Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice
Abstract
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.
Data availability
Data file for metabolomic analysis (Table S1) and statistics of all proteins identified by proteomic analysis (Table S3) have been provided as supplementary materials.The raw mass spec files for proteomics analysis of S-glutathionylation were uploaded to MassIVE and can be accessed via the following link ftp://massive.ucsd.edu/MSV000085329/The raw mass spectrometry files for global proteomic analysis were uploaded to MassIVE and can be accessed via the following link ftp://massive.ucsd.edu/MSV000084961/The image files for ROS (Fig 2a and b) and senescence (Fig 4b and c) analyses can be accessed via the following link and were also included as supporting zip documents. https://www.dropbox.com/sh/0r50ew6xnpunc3t/AAA_HbJ0fQwhOUpDbI9Oq07va?dl=0
Article and author information
Author details
Funding
Glenn Foundation for Medical Research (Glenn/AFAR Postdoctoral Fellowship Program for Translational Research on Aging)
- Ying Ann Chiao
National Institute on Aging (5T32AG000057 Training Grant)
- Ying Ann Chiao
National Institute on Aging (K99/R00 AG051735)
- Ying Ann Chiao
National Institute on Aging (P01 AG001751)
- Peter Rabinovitch
National Institute on Aging (P30 AG013280)
- Peter Rabinovitch
Glenn Foundation for Medical Research (Glenn/AFAR Postdoctoral Fellowship Program for Translational Research on Aging)
- Huiliang Zhang
American Heart Association (CDA 19CDA34660311)
- Huiliang Zhang
National Heart, Lung, and Blood Institute (R35HL144998)
- Henk L Granzier
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Jan Gruber, Yale-NUS College, Singapore
Ethics
Animal experimentation: All mice were handled according to the guidelines of the Institutional Animal Care and Use Committee of the University of Washington and approved IACUC Protocol # 2174-23 . Mice were housed at 20ºC in an AAALAC accredited facility under Institutional Animal Care Committee supervision.
Version history
- Received: January 28, 2020
- Accepted: July 7, 2020
- Accepted Manuscript published: July 10, 2020 (version 1)
- Version of Record published: July 23, 2020 (version 2)
Copyright
© 2020, Chiao et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,898
- Page views
-
- 599
- Downloads
-
- 59
- Citations
Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Medicine
- Neuroscience
Background:
Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine’s molecular mechanisms connect to its neural and behavioral effects.
Methods:
We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition. 40 healthy participants received acute ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr). We quantified resting-state functional connectivity via data-driven global brain connectivity and related it to individual ketamine-induced symptom variation and cortical gene expression targets.
Results:
We found that: (i) both the neural and behavioral effects of acute ketamine are multi-dimensional, reflecting robust inter-individual variability; (ii) ketamine’s data-driven principal neural gradient effect matched somatostatin (SST) and parvalbumin (PVALB) cortical gene expression patterns in humans, while the mean effect did not; and (iii) behavioral data-driven individual symptom variation mapped onto distinct neural gradients of ketamine, which were resolvable at the single-subject level.
Conclusions:
These results highlight the importance of considering individual behavioral and neural variation in response to ketamine. They also have implications for the development of individually precise pharmacological biomarkers for treatment selection in psychiatry.
Funding:
This study was supported by NIH grants DP5OD012109-01 (A.A.), 1U01MH121766 (A.A.), R01MH112746 (J.D.M.), 5R01MH112189 (A.A.), 5R01MH108590 (A.A.), NIAAA grant 2P50AA012870-11 (A.A.); NSF NeuroNex grant 2015276 (J.D.M.); Brain and Behavior Research Foundation Young Investigator Award (A.A.); SFARI Pilot Award (J.D.M., A.A.); Heffter Research Institute (Grant No. 1–190420) (FXV, KHP); Swiss Neuromatrix Foundation (Grant No. 2016–0111) (FXV, KHP); Swiss National Science Foundation under the framework of Neuron Cofund (Grant No. 01EW1908) (KHP); Usona Institute (2015 – 2056) (FXV).
Clinical trial number:
-
- Medicine
The nuclear receptor, farnesoid X receptor (FXR/NR1H4), is increasingly recognized as a promising drug target for metabolic diseases, including nonalcoholic steatohepatitis (NASH). Protein-coding genes regulated by FXR are well known, but whether FXR also acts through regulation of long non-coding RNAs (lncRNAs), which vastly outnumber protein-coding genes, remains unknown. Utilizing RNA-seq and global run-on sequencing (GRO-seq) analyses in mouse liver, we found that FXR activation affects the expression of many RNA transcripts from chromatin regions bearing enhancer features. Among these we discovered a previously unannotated liver-enriched enhancer-derived lncRNA (eRNA), termed FXR-induced non-coding RNA (Fincor). We show that Fincor is specifically induced by the hammerhead-type FXR agonists, including GW4064 and tropifexor. CRISPR/Cas9-mediated liver-specific knockdown of Fincor in dietary NASH mice reduced the beneficial effects of tropifexor, an FXR agonist currently in clinical trials for NASH and primary biliary cholangitis (PBC), indicating that amelioration of liver fibrosis and inflammation in NASH treatment by tropifexor is mediated in part by Fincor. Overall, our findings highlight that pharmacological activation of FXR by hammerhead-type agonists induces a novel eRNA, Fincor, contributing to the amelioration of NASH in mice. Fincor may represent a new drug target for addressing metabolic disorders, including NASH.